COMMUNIQUÉS West-GlobeNewswire

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
21/08/2025
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of [...]
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
20/08/2025
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors [...]
BioAge Labs to Present at Upcoming Investor Conferences
20/08/2025
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]
Onco360® Has Been Selected as a Specialty Pharmacy Partner for HERNEXEOS® (zongertinib)
20/08/2025
LOUISVILLE, K.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos ® (Zongertinib). The [...]
Olema Oncology to Participate in Upcoming Investor Conferences
20/08/2025
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
20/08/2025
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/08/2025
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale [...]
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
20/08/2025
C$0.78 Million Private Placement Successfully Closed TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased [...]
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
20/08/2025
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for [...]
Invivyd Announces Proposed Public Offering of Common Stock
20/08/2025
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends [...]
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
20/08/2025
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a [...]
APIX Biosciences NV announces new advances in Honeybee Nutrition
20/08/2025
WINGENE, Belgium, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Belgian agri-technology company APIX Biosciences NV, active in Europe and the United States, proudly announces the publication in Nature, by APIX Biosciences’ [...]
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement
20/08/2025
COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re- [...]
King Faisal Specialist Hospital Provides Nearly 300,000 Virtual Consultations in 2024
20/08/2025
RIYADH, Saudi Arabia, Aug. 20, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) delivered 293,381 virtual clinic visits in 2024, a 58.2% increase from the previous year. The growth [...]
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
20/08/2025
NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive [...]
OSE Immunotherapeutics nomme Thomas Gidoin au poste de Directeur Financier
20/08/2025
NANTES, France - 20 août 2025, 18 h 00 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , annonce aujourd’hui la nomination de Thomas Gidoin au poste de Directeur Financier. Thomas rejoint le Comité Exécutif [...]
BioAdaptives’ MyndMed™ Receives Full Clearance from TruShield™, Meeting UFC and WADA Standards for Athlete Safety
20/08/2025
Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletes LAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc [...]
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement
20/08/2025
Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030 [...]
BioAegis Therapeutics Awarded Second FDA Fast Track Designation for Recombinant Human Gelsolin to Treat Inflammasome-Driven Decompression Sickness (DCS)
20/08/2025
Fast Track status accelerates regulatory pathway for BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Second Fast Track designation in recent months highlights [...]

Pages